Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Bruxelles  >  ThromboGenics    THR   BE0003846632

THROMBOGENICS (THR)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Bruxelles
07/09/2018 07/10/2018 07/11/2018 07/12/2018 07/13/2018 Date
7.78(c) 8.07(c) 8.92(c) 9.58(c) 10.04(c) Last
143 967 222 324 536 335 441 821 673 635 Volume
-0.89% +3.73% +10.53% +7.40% +4.80% Change
More quotes
Financials (EUR)
Sales 2018 3,00 M
EBIT 2018 -
Net income 2018 -29,0 M
Debt 2018 -
Yield 2018 -
Sales 2019 3,00 M
EBIT 2019 -
Net income 2019 -28,0 M
Debt 2019 -
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
Capi. / Sales2018 128x
Capi. / Sales2019 128x
Capitalization 384 M
More Financials
Company
ThromboGenics NV is a biopharmaceutical company, which engages in developing and commercializing medicines for the treatment of vitreo retinal diseases.It operates under JETREA (ocriplasmin) brand name.The company was founded by Desire Collen in 1991 and is headquartered in Leuven, Belgium. 
More about the company
Latest news on THROMBOGENICS
06/28THROMBOGENICS : Plans Name Change to "Oxurion"
AQ
06/27THROMBOGENICS : Plans Name Change to “Oxurion”
PU
06/27THROMBOGENICS : Plans Name Change to "Oxurion"
GL
06/21THROMBOGENICS : Partners with Prevent Blindness at 2018 Focus on Eye Health Nati..
GL
06/21ThromboGenics Partners with Prevent Blindness at 2018 Focus on Eye Health Nat..
GL
06/07THROMBOGENICS : Bicycle Therapeutics Announces Clinical Milestone & Expands Coll..
AQ
05/29THROMBOGENICS : begins phase 1 study evaluating safety of THR-149 to treat diabe..
AQ
05/26THROMBOGENICS : Bicycle Therapeutics Announces Clinical Milestone & Expands Coll..
AQ
05/26THROMBOGENICS : Enrolls First Patient in Phase 1 Clinical Study Evaluating THR-1..
AQ
05/25THROMBOGENICS : Enrolls First Patient in Phase 1 Clinical Study Evaluating THR-1..
PU
More news
Sector news : Biotechnology & Medical Research - NEC
07/09LONZA : restates 2017 figures after changing accounting standard
RE
07/03Sanofi beefs up diabetes pipeline to retrieve success
RE
06/29European stocks shrug off trade worries with quarterly gain
RE
06/29GILEAD SCIENCES : Rival Novartis, Gilead CAR-T therapies win European panel reco..
RE
06/20GILEAD SCIENCES : GSK takes billion-dollar drug fight with Gilead to top AIDS me..
RE
More sector news : Biotechnology & Medical Research - NEC
4-Traders Strategies on THROMBOGENICS 
THROMBOGENICS - 2012
The bullish trend continues
BUY
More Strategies
Latest Tweets
06/27ThromboGenics plans name change to “Oxurion”  
06/27ThromboGenics Plans Name Change to "Oxurion"  
06/21ThromboGenics Partners with Prevent Blindness at 2018 Focus on Eye Health Nat.. 
05/29Most of the PC's ideas are long overdue, but getting politics out of the sect.. 
05/28This is interesting. 's Paul Howes warns against over-regulation in the wake .. 
More tweets
Qtime:47
News from SeekingAlpha
06/27ThromboGenics plans name change to ?Oxurion? 
05/25ThromboGenics enrolls first patient in Phase 1 clinical study evaluating THR-.. 
04/27ThromboGenics commences mid-stage study of THR-317/Lucentis combo in DME 
04/11FDA OKs AI software to detect diabetic retinopathy 
2017YOUR DAILY PHARMA SCOOP : Celgene Upside, Erytech Tumbles, Novartis Neulasta Bio.. 
Chart THROMBOGENICS
Duration : Period :
ThromboGenics Technical Analysis Chart | THR | BE0003846632 | 4-Traders
Technical analysis trends THROMBOGENICS
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 1
Average target price 5,00 €
Spread / Average Target -50%
Managers
NameTitle
Patrik de Haes Chief Executive Officer & Executive Director
Thomas Moragne Clay Chairman
Dominique Vanfleteren Chief Financial Officer
Susan Schneider Chief Medical Officer
David R. Guyer Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
THROMBOGENICS196.78%449
CELLTRION, INC.--.--%31 997
IQVIA HOLDINGS INC9.57%22 131
LONZA GROUP9.72%21 465
INCYTE CORPORATION-25.89%14 878
SEATTLE GENETICS, INC.31.68%11 147